clinical trial · NCT06378242
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
RemeGen Co., Ltd.·phase2·recruiting·n = 24
High-risk Non-muscle Invasive Bladder CancerDisitamab Vedotin for injection
brief summary
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2
started
Jun 14, 2024
primary completion
Mar 15, 2029
completion
Dec 31, 2029
last updated
Jul 11, 2024
detailed description
This is a single-arm, multicenter phase I/II clinical study to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2.
official title
An Single-arm, Multicenter Phase I/II Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol